Join
Live feed
·
PRReleasevia Quantisnow
DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

ByQuantisnow·Wall Street's wire, on your screen.
DMAC· DiaMedica Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DMAC (DiaMedica Therapeutics Inc.) and more on Quantisnow.